Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.

[1]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[2]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[3]  L. Martínez-Piñeiro,et al.  The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. , 2011, European urology.

[4]  M. Stockler,et al.  Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomize , 2011, European urology.

[5]  G. Sonpavde,et al.  Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer , 2011, Expert review of anticancer therapy.

[6]  A. Bohle.  Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993) , 2011 .

[7]  C. Busch,et al.  Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). , 2011, European urology.

[8]  A. Bohle.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer , 2009 .

[9]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[10]  T. Griffith,et al.  Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. , 2009, Immunotherapy.

[11]  T. Ratliff,et al.  The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity , 2008, Cancer Immunology, Immunotherapy.

[12]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[13]  A. Böhle,et al.  Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. , 2004, Urology.

[14]  P. Malmström,et al.  Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. , 2003, European urology.

[15]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[16]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[17]  P. Allen,et al.  Characterization of the Fibronectin Binding Motif for a Unique Mycobacterial Fibronectin Attachment Protein, FAP* , 1999, The Journal of Biological Chemistry.

[18]  T. Ratliff,et al.  Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. , 1987, Cancer research.

[19]  M. Valenti,et al.  Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. , 2006, The Lancet. Oncology.

[20]  K. Jauhiainen,et al.  Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and Interferon-α , 2004, Urological Research.

[21]  A. Böhle,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.

[22]  L. Kavoussi,et al.  Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. , 1990, The Journal of clinical investigation.